News for Zai Lab Limited (ZLAB)

The consensus price target hints at a 64.4% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor conf

Zai Lab Limited (NASDAQ:ZLAB) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ETCompany ParticipantsChristine Chiou - Senior Vice President, Head...

The following slide deck was published by Zai Lab Limited in conjunction with their 2024 Q4 earnings call.

Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2024. Novocure is a global oncology company working t

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the fourth quarter and full-year 2024, along with recent product highlights an

Zai Lab Limited (ZLAB), while reporting narrower loss and higher revenues in its fourth quarter, on Thursday said it expects to achieve profitability on an adjusted basis in the fourth quarter of 2025.

**media[551690]**

Zai Lab Limited (ZLAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zai Lab Limited (ZLAB) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

PR NewswireSAN DIEGO, Feb. 18, 2025 Fourth Quarter Total Revenue Increased 30% YOY to $298 million and Royalty Revenue Increased 40% YOY to $170 millionFou

**media[532689]**

Baron International Growth Fund declined 5.90% (inst.) during the final quarter of 2024. Click here to read the full commentary.

The consensus price target hints at a 95.6% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

PR NewswireSHANGHAI, Jan. 27, 2025 SHANGHAI, Jan. 27, 2025 /PRNewswire/ -- On January 27th, 2025, Beijing Time, Qiming Venture Partners' portfolio company

We recently compiled a list of the Billionaire Andreas Halvorsen's Top 15 Long-Term Stock Picks. In this article, we are going to take a look at where Zai Lab Limited (NASDAQ:ZLAB) stands against Andreas...

While the stock market in the United States remained closed on January 20 for Martin Luther King, Jr. Day, the day was happening with Donald Trump's inauguration on the same date.

Chinese regulators have accepted Zai Lab's market application for the schizophrenia drug KarXT, which is marketed by Bristol-Myers in the U.S. as Cobenfy. Read more here.

Zai Lab (ZLAB) stock rose after positive trial data for its cervical cancer drug Tivdak and its plans to seek marketing approval for the drug in China. Read more here.